Dragonboat Activity for Breast Cancer

计划入组 32 人 · 首次发布于 2022 年 1 月 25 日

Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers

计划入组 20 人 · 首次发布于 2010 年 8 月 6 日

Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients

计划入组 156 人 · 首次发布于 2014 年 4 月 17 日

BC-007

Epilepsy(Merdury Biopharmaceutical )

CS-02(Zhongshan Hengdong Biopharmaceutical)

Sino Biopharmaceutical Limited

China

Asklepios Biopharmaceutical, Inc.

United States

Tariqi Biopharmaceutical Co., Ltd.

China

Dragonboat Biopharmaceutical Advances Cetuximab Biosimilar Development for Multiple Cancer Indications

PharmaEssentia Launches BESREMi® in Singapore for Polycythemia Vera Treatment

Biopharmaceutical Innovation: The Patent Imperative Under Siege